Literature DB >> 29934472

Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells.

Filippos Porichis1, Meghan G Hart1, Alexandra Massa1, Holly L Everett1, Antigoni Morou2, Jonathan Richard2, Nathalie Brassard2, Maxime Veillette2, Muska Hassan1, Ngoc Le Ly1, Jean-Pierre Routy3,4, Gordon J Freeman5,6, Mathieu Dubé2, Andrés Finzi2, Daniel E Kaufmann7,8.   

Abstract

Immune exhaustion is an important feature of chronic infections, such as HIV, and a barrier to effective immunity against cancer. This dysfunction is in part controlled by inhibitory immune checkpoints. Blockade of the PD-1 or IL-10 pathways can reinvigorate HIV-specific CD4 T cell function in vitro, as measured by cytokine secretion and proliferative responses upon Ag stimulation. However, whether this restoration of HIV-specific CD4 T cells can improve help to other cell subsets impaired in HIV infection remains to be determined. In this study, we examine a cohort of chronically infected subjects prior to initiation of antiretroviral therapy (ART) and individuals with suppressed viral load on ART. We show that IFN-γ induction in NK cells upon PBMC stimulation by HIV Ag varies inversely with viremia and depends on HIV-specific CD4 T cell help. We demonstrate in both untreated and ART-suppressed individuals that dual PD-1 and IL-10 blockade enhances cytokine secretion of NK cells via restored HIV-specific CD4 T cell function, that soluble factors contribute to these immunotherapeutic effects, and that they depend on IL-2 and IL-12 signaling. Importantly, we show that inhibition of the PD-1 and IL-10 pathways also increases NK degranulation and killing of target cells. This study demonstrates a previously underappreciated relationship between CD4 T cell impairment and NK cell exhaustion in HIV infection, provides a proof of principle that reversal of adaptive immunity exhaustion can improve the innate immune response, and suggests that immune checkpoint modulation that improves CD4/NK cell cooperation can be used as adjuvant therapy in HIV infection.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29934472      PMCID: PMC6064609          DOI: 10.4049/jimmunol.1701551

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

Review 1.  T follicular helper cell differentiation, function, and roles in disease.

Authors:  Shane Crotty
Journal:  Immunity       Date:  2014-10-16       Impact factor: 31.745

2.  CD16- natural killer cells: enrichment in mucosal and secondary lymphoid tissues and altered function during chronic SIV infection.

Authors:  R Keith Reeves; Jacqueline Gillis; Fay E Wong; Yi Yu; Michelle Connole; R Paul Johnson
Journal:  Blood       Date:  2010-03-25       Impact factor: 22.113

3.  CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity.

Authors:  Todd A Fehniger; Megan A Cooper; Gerard J Nuovo; Marina Cella; Fabio Facchetti; Marco Colonna; Michael A Caligiuri
Journal:  Blood       Date:  2002-12-12       Impact factor: 22.113

4.  Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells.

Authors:  Shayarana L Gooneratne; Jonathan Richard; Wen Shi Lee; Andrés Finzi; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

5.  T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus.

Authors:  Xiao-Song He; Monia Draghi; Kutubuddin Mahmood; Tyson H Holmes; George W Kemble; Cornelia L Dekker; Ann M Arvin; Peter Parham; Harry B Greenberg
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina.

Authors:  Michelle N Kelly; Mingquan Zheng; Sanbao Ruan; Jay Kolls; Alain D'Souza; Judd E Shellito
Journal:  J Immunol       Date:  2012-11-30       Impact factor: 5.422

8.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction.

Authors:  Daniel E Kaufmann; Daniel G Kavanagh; Florencia Pereyra; John J Zaunders; Elizabeth W Mackey; Toshiyuki Miura; Sarah Palmer; Mark Brockman; Almas Rathod; Alicja Piechocka-Trocha; Brett Baker; Baogong Zhu; Sylvie Le Gall; Michael T Waring; Ryan Ahern; Kristin Moss; Anthony D Kelleher; John M Coffin; Gordon J Freeman; Eric S Rosenberg; Bruce D Walker
Journal:  Nat Immunol       Date:  2007-09-30       Impact factor: 25.606

9.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

10.  CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART.

Authors:  Rémi Fromentin; Wendy Bakeman; Mariam B Lawani; Gabriela Khoury; Wendy Hartogensis; Sandrina DaFonseca; Marisela Killian; Lorrie Epling; Rebecca Hoh; Elizabeth Sinclair; Frederick M Hecht; Peter Bacchetti; Steven G Deeks; Sharon R Lewin; Rafick-Pierre Sékaly; Nicolas Chomont
Journal:  PLoS Pathog       Date:  2016-07-14       Impact factor: 6.823

View more
  23 in total

1.  Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV.

Authors:  Geetha H Mylvaganam; Lynette S Chea; Gregory K Tharp; Sakeenah Hicks; Vijayakumar Velu; Smita S Iyer; Claire Deleage; Jacob D Estes; Steven E Bosinger; Gordon J Freeman; Rafi Ahmed; Rama R Amara
Journal:  JCI Insight       Date:  2018-09-20

2.  Increased Frequency of Virus Shedding by Herpes Simplex Virus 2-Infected Guinea Pigs in the Absence of CD4+ T Lymphocytes.

Authors:  Nigel Bourne; Clarice L Perry; Brianne N Banasik; Aaron L Miller; Mellodee White; Richard B Pyles; Hubert Schäfer; Gregg N Milligan
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

4.  Treatment of Relapsing HPV Diseases by Restored Function of Natural Killer Cells.

Authors:  Andrea Lisco; Amy P Hsu; Dimana Dimitrova; Diana M Proctor; Emily M Mace; Peiying Ye; Megan V Anderson; Stephanie N Hicks; Christopher Grivas; Dima A Hammoud; Maura Manion; Gabriel J Starrett; Alvin Farrel; Kerry Dobbs; Isaac Brownell; Christopher Buck; Luigi D Notarangelo; Jordan S Orange; Warren J Leonard; Michael I Orestes; Anju T Peters; Jennifer A Kanakry; Julia A Segre; Heidi H Kong; Irini Sereti
Journal:  N Engl J Med       Date:  2021-09-02       Impact factor: 176.079

Review 5.  The single-cell landscape of immunological responses of CD4+ T cells in HIV versus severe acute respiratory syndrome coronavirus 2.

Authors:  Jack A Collora; Runxia Liu; Kristen Albrecht; Ya-Chi Ho
Journal:  Curr Opin HIV AIDS       Date:  2021-01       Impact factor: 4.283

6.  Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.

Authors:  Helen R Wagstaffe; Elizabeth A Clutterbuck; Viki Bockstal; Jeroen N Stoop; Kerstin Luhn; Macaya Douoguih; Georgi Shukarev; Matthew D Snape; Andrew J Pollard; Eleanor M Riley; Martin R Goodier
Journal:  J Clin Invest       Date:  2020-07-01       Impact factor: 14.808

Review 7.  Monkeying Around: Using Non-human Primate Models to Study NK Cell Biology in HIV Infections.

Authors:  Cordelia Manickam; Spandan V Shah; Junsuke Nohara; Guido Ferrari; R Keith Reeves
Journal:  Front Immunol       Date:  2019-05-22       Impact factor: 7.561

8.  Natural Killer Cells Integrate Signals Received from Tumour Interactions and IL2 to Induce Robust and Prolonged Anti-Tumour and Metabolic Responses.

Authors:  Nidhi Kedia-Mehta; Chloe Choi; Aisling McCrudden; Elisabeth Littwitz-Salomon; Proinnsias G Fox; Clair M Gardiner; David K Finlay
Journal:  Immunometabolism       Date:  2019-09-25

9.  A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma.

Authors:  Fathima Zumla Cader; Xihao Hu; Walter L Goh; Kirsty Wienand; Jing Ouyang; Elisa Mandato; Robert Redd; Lee N Lawton; Pei-Hsuan Chen; Jason L Weirather; Ron C J Schackmann; Bo Li; Wenjiang Ma; Philippe Armand; Scott J Rodig; Donna Neuberg; X Shirley Liu; Margaret A Shipp
Journal:  Nat Med       Date:  2020-08-10       Impact factor: 53.440

10.  Upregulation of Multiple CD8+ T Cell Exhaustion Pathways Is Associated with Recurrent Ocular Herpes Simplex Virus Type 1 Infection.

Authors:  Pierre-Grégoire Coulon; Soumyabrata Roy; Swayam Prakash; Ruchi Srivastava; Nisha Dhanushkodi; Stephanie Salazar; Cassandra Amezquita; Lan Nguyen; Hawa Vahed; Angela M Nguyen; Wasay R Warsi; Caitlin Ye; Edgar A Carlos-Cruz; Uyen T Mai; Lbachir BenMohamed
Journal:  J Immunol       Date:  2020-06-15       Impact factor: 5.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.